Storia della carriera di James Smith
Precedenti posizioni note di James Smith
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| SIERRA ONCOLOGY, INC. | Contatto Relazioni con gli Investitori | 22/10/2014 | 01/12/2020 |
| Corporate Officer/Principal | 01/12/2020 | 01/07/2022 | |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Contatto Relazioni con gli Investitori | 01/01/2011 | 01/01/2014 |
| Public Communications Contact | 01/01/2011 | 01/01/2014 | |
| SQI DIAGNOSTICS INC. | Corporate Officer/Principal | 01/01/2014 | - |
Formazione di James Smith
| Queen's University | Graduate Degree |
| LaTrobe University | Masters Business Admin |
Statistiche
Distribuzione geografica
| Canada | 4 |
| Stati Uniti | 2 |
| Australia | 2 |
Posizioni
| Investor Relations Contact | 2 |
| Corporate Officer/Principal | 2 |
| Public Communications Contact | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SQI DIAGNOSTICS INC. | Health Technology |
| Aziende private | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
- Borsa valori
- Insiders
- James Smith
- Esperienza
